Claims for Patent: 9,255,270

Summary for Patent: 9,255,270

Title:	Methods used in sensitizing invasive glioblastoma to therapeutic treatment
Abstract:	The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy.
Inventor(s):	Tran; Nhan (Phoenix, AZ)
Assignee:	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (Phoenix, AZ)
Application Number:	14/213,570
Patent Claims:	1. A method of characterizing a brain tumor as invasive and sensitizing the invasive tumor for treatment, the method comprising the steps of: adding a reagent capable of binding to a marker selected from the group consisting of SEQ ID NO. 3 and SEQ ID NO. 4 to a mixture comprising a sample of the tumor; subjecting the mixture to conditions that allow detection of binding of the reagent to the marker; classifying the tumor as invasive when the binding of the reagent to the marker is increased in the sample compared to a control brain sample, which reflects an increased expression level of the marker in the sample compared to the control brain sample; and reducing the expression level of the marker by local administration of small interfering RNAs targeting the nucleic acid encoding the marker to sensitize the invasive tumor to a treatment when the binding of the reagent to the marker is increased compared to the control brain sample. 2. The method of claim 1, wherein sensitizing the invasive tumor induces apoptosis in at least a portion of cells of the tumor upon administration of the treatment. 3. The method of claim 1 and further comprising administering a therapeutically effective amount of the treatment to the patient. 4. The method of claim 3, wherein the treatment comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3K inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab. 5. The method of claim 1, wherein the invasive tumor comprises glioblastoma. 6. The method of claim 1, wherein the sample is selected from the group consisting of brain tissues, fluid samples, and single cells. 7. The method of claim 1, wherein the small interfering RNAs comprise oligonucleotides. 8. A method of characterizing a brain tumor as invasive and sensitizing the invasive tumor for treatment, the method comprising the steps of: obtaining a sample from the tumor; adding a reagent capable of binding to a marker selected from the group consisting of SEQ ID NO. 3 and SEQ ID NO. 4 to a mixture comprising the sample; subjecting the mixture to conditions that allow detection of the binding of the reagent to the marker; classifying the tumor as an invasive when the binding of the reagent to the marker in the sample is more than twice the binding of the reagent to a control brain sample, which reflects an increased expression level of the marker in the sample compared to the control brain sample; and reducing the expression level of the marker by local administration of small interfering RNAs targeting the nucleic acid encoding the marker to sensitize the invasive tumor to a treatment when the tumor is classified as invasive. 9. The method of claim 8 and further comprising administering a therapeutically effective amount of the treatment to the patient. 10. The method of claim 9, wherein the treatment comprises the administration of one or more compounds selected from the group consisting of TROY inhibitors, Pyk2 inhibitors, Rac1 inhibitors, Dock180 inhibitors, Dock7 inhibitors, TWEAK inhibitors, Fn14 inhibitors, BAD inhibitors, and PI3K inhibitors, TRAIL, camptothecin, temozolomide and bevacizumab. 11. The method of claim 8, wherein the invasive tumor comprises glioblastoma. 12. The method of claim 8, wherein the small interfering RNAs comprise oligonucleotides.

Details for Patent 9,255,270

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2030-10-25